ClinicalTrials.gg
TerminatedNCT02088957Updated Jul 11, 2018Results posted

Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures

A Phase 2 interventional study of Brivaracetam intravenous solution and Brivaracetam oral tablets in Nonconvulsive Electrographic Seizures, sponsored by UCB BIOSCIENCES, Inc.. Terminated at 2 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-07-11.

Sponsored by UCB BIOSCIENCES, Inc. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Termination of study due to low enrollment. There were no safety issues.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Seizures by UCB S.A. — 3 open to participants now, 4 under way, 4 of them phase 3. Seizures · UCB S.A..

Enrollment
36th of 36
1 · median 102
Started
2014
the only one that year
Phase 2
8 of 40
none open now
Registered
25th of 40
by date

Among the 40 studies in Seizures by UCB S.A., this one is the 36th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2014, is one of 8 in phase 2, and was the 25th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

3 of the 40 studies in Seizures by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Seizures by UCB S.A., or all of them as a file.
02

Study summary

The primary objective of this study is to compare the efficacy of Brivaracetam and Phenytoin, both administered intravenously, in adult subjects experiencing nonconvulsive electrographic seizures.

03

Conditions studied

  • Nonconvulsive Electrographic Seizures

Browse trials for

Keywords

  • Brivaracetam
  • Phenytoin
  • Nonconvulsive electrographic seizures
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥16 years. Subjects under 18 years may only be included where legally permitted and ethically accepted
  • Subjects in the neurological intensive care unit (NICU) (or equivalent closely monitored environment) having brain insult including traumatic brain injury and having nonconvulsive electrographic seizures (NCES) confirmed by electroencephalogram (EEG), lasting a minimum of 10 seconds but not >30 minutes (minimum of 1 seizure in the last 6 hours) and treatment with an antiepileptic drug (AED) is required according to the physician's clinical judgment
  • Subject is expected to be under cEEG monitoring with video surveillance in the Neuro ICU for at least 36 hours from the first administration of study drug

Exclusion criteria

Exclusion Criteria:

  • Subject has history of severe adverse hematologic or cutaneous reaction to any drug
  • Subject presenting with status epilepticus or nonconvulsive status epilepticus (NCSE) (ie, 1 continuous, convulsive or nonconvulsive, unremitting seizure lasting >30 minutes during Visit 1)
  • Subject has been diagnosed with anoxic brain injury
  • Subject has a known history of status epilepticus during the 6 months preceding Visit 1
  • Subject is currently treated with Levetiracetam (LEV) or Phenytoin (PHT) or has been treated within the last 30 days before Visit 1 with LEV or PHT
  • Subject is on felbamate with \<18 months' exposure before Visit 1
  • Subject has presence of any sign (clinical or imaging techniques) suggesting a rapidly progressing process such that the subject is not expected to survive >48 hours
  • Subject has any clinical condition that would impair reliable participation in the study or necessitate the use of medications not allowed by the protocol
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Brivaracetam

    Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months. Subjects should transition to oral medication as soon as they are able to swallow tablets.

    Drug: Brivaracetam intravenous solution · Drug: Brivaracetam oral tablets

  • Active comparator
    Phenytoin

    Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months. Subjects should transition to oral medication as soon as they are able to swallow tablets.

    Drug: Phenytoin intravenous solution · Drug: Phenytoin oral tablets

Interventions

  • * Active Substance: Brivaracetam * Pharmaceutical Form: Solution for infusion * Concentration: 10 mg/mL * Route of Administration: Intravenous bolus use

  • * Active Substance: Brivaracetam * Pharmaceutical Form: Film-coated tablet * Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid) * Route of Administration: Oral use

  • * Active Substance: Phenytoin * Pharmaceutical Form: Solution for infusion * Concentration: 50 mg/mL * Route of Administration: Intravenous use

  • * Active Substance: Phenytoin * Pharmaceutical Form: Tablet * Concentration: Weight based * Route of Administration: Oral use

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Seizure Freedom for 12 Hours Based on cEEG/vEEG Monitoring Which Starts 1 Hour After the End of the Last Acute iv Administration of Study Drug and Prior to the Initiation of Bid (Twice a Day) Dosing

    Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

    Time frame: From 1 hour after end of the last acute iv administration of study drug and prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)

Secondary outcomes

  1. Percentage of Subjects With Seizure Freedom for 12 Hours Based on cEEG/vEEG Monitoring Which Starts After the End of the Last Acute Intravenous (iv) Administration of Study Drug and Prior to the Initiation of Bid (Twice a Day) Dosing

    Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

    Time frame: From end of the last acute iv administration of study drug and prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)

  2. Time to Achievement of 12 Hours of Seizure Freedom Relative to the Start of the First Acute Intravenous (iv) Administration

    Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

    Time frame: From start of first acute iv administration on Day 1

  3. Time to Achievement of 12 Hours of Seizure Freedom Relative to the Start of the Last Acute Intravenous (iv) Administration That Occurred Prior to the Initiation of Bid (Twice a Day) Dosing

    Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

    Time frame: From start of last acute iv administration prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)

  4. Percentage of Subjects Requiring a Second Acute Intravenous (iv) Administration Between 15 Minutes to 12 Hours After First Acute iv Administration

    Time frame: Between 15 minutes to 12 hours after first acute iv administration

  5. Time to First Onset of Seizure Cessation Relative to the Start of the First Acute Intravenous (iv) Administration

    Seizure cessation is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

    Time frame: From start of first acute iv administration

07

Results

Posted Apr 13, 2016

Participant flow

Sixty subjects were planned to be screened in order to enroll 50 subjects in a 1:1 ratio to intravenous (iv) Brivaracetam (BRV) or iv Phenytoin (PHT) with stratification based on categorized age (\<65 years versus ≥65 years) across approximately 15 sites.

Participant flow — Overall Study
MilestoneBrivaracetamPhenytoin
Started10
Completed00
Not completed10
Withdrew: Lack of efficacy10

Outcome measures

PrimaryPercentage of Subjects With Seizure Freedom for 12 Hours Based on cEEG/vEEG Monitoring Which Starts 1 Hour After the End of the Last Acute iv Administration of Study Drug and Prior to the Initiation of Bid (Twice a Day) Dosing

Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

Time frame:
From 1 hour after end of the last acute iv administration of study drug and prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)

No measurements were reported for this outcome.

SecondaryPercentage of Subjects With Seizure Freedom for 12 Hours Based on cEEG/vEEG Monitoring Which Starts After the End of the Last Acute Intravenous (iv) Administration of Study Drug and Prior to the Initiation of Bid (Twice a Day) Dosing

Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

Time frame:
From end of the last acute iv administration of study drug and prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)

No measurements were reported for this outcome.

SecondaryTime to Achievement of 12 Hours of Seizure Freedom Relative to the Start of the First Acute Intravenous (iv) Administration

Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

Time frame:
From start of first acute iv administration on Day 1

No measurements were reported for this outcome.

SecondaryTime to Achievement of 12 Hours of Seizure Freedom Relative to the Start of the Last Acute Intravenous (iv) Administration That Occurred Prior to the Initiation of Bid (Twice a Day) Dosing

Seizure freedom is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

Time frame:
From start of last acute iv administration prior to initiation of bid dosing (which begins 12 hours after the last acute iv administration of study drug)

No measurements were reported for this outcome.

SecondaryPercentage of Subjects Requiring a Second Acute Intravenous (iv) Administration Between 15 Minutes to 12 Hours After First Acute iv Administration
Time frame:
Between 15 minutes to 12 hours after first acute iv administration

No measurements were reported for this outcome.

SecondaryTime to First Onset of Seizure Cessation Relative to the Start of the First Acute Intravenous (iv) Administration

Seizure cessation is based on cEEG/vEEG (continuous video electroencephalogram) monitoring.

Time frame:
From start of first acute iv administration

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events were collected during the 75 days the only subject was included in this study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam—0/1 (0%)1/1 (100%)
Phenytoin———
Most frequent other events
Most frequent other events
EventBrivaracetamPhenytoin
ConstipationGastrointestinal disorders1/1—
Decreased appetiteMetabolism and nutrition disorders1/1—
Decreased urinary outputInvestigations1/1—
iv infiltrationGeneral disorders1/1—
Failure to thriveMetabolism and nutrition disorders1/1—

Baseline characteristics

Demographics of the only subject included are presented below.

Age, Categorical
Age, Categorical(Participants)Brivaracetam
<=18 years0
Between 18 and 65 years1
>=65 years0
Age, Continuous
Age, Continuous(years)Brivaracetam
Mean18 ± 0
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam
Female1
Male0
08

Study locations

2 sites
  • 3
    Lexington, Kentucky, United States
  • 1
    Jackson, Mississippi, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 6 months after primary completion. A results delay was requested in Jul 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2014
First posted
Mar 17, 2014
Start
Mar 2014
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results delay requested
Jul 21, 2015
Results first posted
Apr 13, 2016
Last update
Jul 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02088957
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Mar 17, 2014
Start date
Mar 2014
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Apr 13, 2016
Last update
Jul 11, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion